These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18347611)

  • 1. Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke.
    Schelleman H; Klungel OH; Witteman JC; Breteler MM; Hofman A; van Duijn CM; de Boer A; Stricker BH
    Pharmacogenomics J; 2008 Dec; 8(6):400-7. PubMed ID: 18347611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers.
    Schelleman H; Klungel OH; Witteman JC; Breteler MM; Yazdanpanah M; Danser AH; Hofman A; van Duijn CM; de Boer A; Stricker BH
    Eur J Hum Genet; 2007 Apr; 15(4):478-84. PubMed ID: 17299437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variation in the renin--angiotensin system, use of renin--angiotensin system inhibitors and the risk of myocardial infarction.
    Maitland-van der Zee AH; van Wieren-de Wijer DB; de Boer A; Kroon AA; de Leeuw PW; Schiffers P; Janssen RG; Psaty BM; van Duijn CM; Stricker BH; Klungel OH
    J Renin Angiotensin Aldosterone Syst; 2011 Sep; 12(3):208-14. PubMed ID: 21163865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives.
    Bozkurt O; Verschuren WM; van Wieren-de Wijer BM; Knol MJ; de Boer A; Grobbee DE; Geerlings MI; Heerdink ER; Klungel OH
    J Hum Hypertens; 2008 Nov; 22(11):774-80. PubMed ID: 18563171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or beta-blockers and the risk of atherosclerosis.
    Schelleman H; Klungel OH; Witteman JC; Hofman A; van Duijn CM; de Boer A; Stricker BH
    Br J Clin Pharmacol; 2007 Jul; 64(1):57-66. PubMed ID: 17298481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes.
    Bozkurt O; de Boer A; Grobbee DE; Kroon AA; Schiffers P; de Leeuw P; Klungel OH
    J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):101-8. PubMed ID: 19502258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.
    McNamara DM; Holubkov R; Postava L; Janosko K; MacGowan GA; Mathier M; Murali S; Feldman AM; London B
    J Am Coll Cardiol; 2004 Nov; 44(10):2019-26. PubMed ID: 15542286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diuretic-gene interaction and the risk of myocardial infarction and stroke.
    Schelleman H; Klungel OH; Witteman JC; Breteler MM; Hofman A; van Duijn CM; de Boer A; Stricker BH
    Pharmacogenomics J; 2007 Oct; 7(5):346-52. PubMed ID: 17189961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
    Böger CA; Götz AK; Krüger B; Hösl M; Schmitz G; Riegger GA; Krämer BK
    Eur J Med Res; 2005 Apr; 10(4):161-8. PubMed ID: 15946912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms in the renin-angiotensin system confer increased risk of stroke independently of blood pressure: a nested case-control study.
    Möllsten A; Stegmayr B; Wiklund PG
    J Hypertens; 2008 Jul; 26(7):1367-72. PubMed ID: 18551012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].
    Arós F; Loma-Osorio A; Vila J; López-Bescós L; Cuñat J; Rodríguez E; San José JM; Heras M; Marrugat J;
    Rev Esp Cardiol; 2006 Apr; 59(4):313-20. PubMed ID: 16709383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke.
    Lemaitre RN; Heckbert SR; Sotoodehnia N; Bis JC; Smith NL; Marciante KD; Hindorff LA; Lange LA; Lumley TS; Rice KM; Wiggins KL; Psaty BM
    Am J Hypertens; 2008 Mar; 21(3):290-6. PubMed ID: 18219297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic interactions of renin-angiotensin system genes in myocardial infarction.
    Araújo MA; Goulart LR; Cordeiro ER; Gatti RR; Menezes BS; Lourenço C; Silva HD
    Int J Cardiol; 2005 Aug; 103(1):27-32. PubMed ID: 16061119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Association between renin-angiotensin system gene polymorphism and type 2 diabetics with stroke in China].
    Zhang X; Wang D; Xu L; Ma Y; Zhang S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2001 Dec; 18(6):462-6. PubMed ID: 11774217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
    J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-angiotensin-aldosterone system polymorphisms: a role or a hole in occurrence and long-term prognosis of acute myocardial infarction at young age.
    Franco E; Palumbo L; Crobu F; Anselmino M; Frea S; Matullo G; Piazza A; Trevi GP; Bergerone S
    BMC Med Genet; 2007 May; 8():27. PubMed ID: 17519002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-gene interaction between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and antihypertensive therapy.
    Schelleman H; Klungel OH; van Duijn CM; Witteman JC; Hofman A; de Boer A; Stricker BH
    Ann Pharmacother; 2006 Feb; 40(2):212-8. PubMed ID: 16449550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure.
    Schelleman H; Klungel OH; Witteman JC; Hofman A; van Duijn CM; de Boer A; Stricker BH
    Eur J Hum Genet; 2006 Jul; 14(7):860-6. PubMed ID: 16724011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal function dependent association of AGTR1 polymorphism (A1166C) and electrocardiographic left-ventricular hypertrophy.
    Smilde TD; Zuurman MW; Hillege HL; van Veldhuisen DJ; van Gilst WH; van der Steege G; Voors AA; Kors JA; de Jong PE; Navis G
    Am J Hypertens; 2007 Oct; 20(10):1097-103. PubMed ID: 17903694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.